The stock price touched the abnormal volatility standard of stock trading, and Yaben Chemical received a letter of concern from the Shenzhen Stock Exchange

Finance network capital market news, on January 20, because the stock price touched the abnormal fluctuation standard of stock trading, Yaben Chemical received a letter of concern from the Shenzhen Stock Exchange.

The cumulative increase of Yaben Chemical's stock price since November 1, 2021 has reached 432.55%, which deviates greatly from the ChiNext Composite Index in the same period, during which it touched the standard of serious abnormal volatility in stock trading on December 28, 2021 and the abnormal volatility standard of stock trading on January 14, 2022. The Shenzhen Stock Exchange is concerned about this and asks Aben Chemical to verify and further explain the following matters:

First, on November 4, 2021, Yaben Chemical released a message on the official website that "the commercial mass production of the pharmaceutical intermediate carolongic anhydride developed and produced has been smooth, and the current monthly production scale has reached 20 tons", and the next day, Pfizer announced its interim clinical data on the new crown oral drug. Since November 5, investors have repeatedly inquired about the business related to Caroline anhydride of Aben Chemical and whether it directly or indirectly supplies Pfizer, whether the Company's carolong anhydride products are intermediates for Pfizer's new crown oral drug, and whether they meet the needs of Pfizer products. On November 12, some investors mentioned in Yaben Chemical Interactive that "carolongic anhydride is the main or only API in the upstream of Pfizer anti-new crown oral drug".

(1) Please explain the reasons for publishing the commercial mass production information of carolongic anhydride on the official website, whether the above information meets the information disclosure standards, whether it is information that has a significant impact on the company's stock price, and whether There are any information disclosure violations in Yaben Chemical. Please indicate whether At the time of publication of the above information, Yaben Chemicals was aware that Pfizer's raw materials for COVID-19 oral drugs may involve carolong anhydride, and if not, please indicate the time when Yaben Chemicals became aware of the possible involvement of carolong anhydride-related raw materials for Pfizer's NEW CORONAVIRUS oral medicines. Please ask Yaben Chemical to explain whether the company's mass production of related products is released through the official website, whether The operation of Yaben Chemical to release the commercial mass production information of carophenic anhydride through the official website is consistent with the company's usual practice, and whether Yaben Chemical has released information through the official website to rub the hot spots of new crown drugs.

(2) Please explain the reasons why Yaben Chemical did not clearly reply to the investors' above-mentioned questions in Interactive Easy, whether the relevant matters replied to belong to the information that has a significant impact on the company's stock price, and after the abnormal fluctuations in the company's stock trading on December 22, Yaben Chemical only explained in the announcement of the change that there was no direct cooperative relationship with Pfizer, and still did not make a clear explanation of the reasons for the investors' concerns about "whether the company's carlonic anhydride products are Pfizer's new crown oral drug intermediates" and "whether they meet the needs of Pfizer products". And verify whether the relevant interactive easy reply and the content of the announcement are true, accurate and complete, and whether it is suspected of misleading investors.

(3) Please combine the specific circumstances of Yaben Chemical's response to investors' relevant questions since November 2021, participate in investor relations activities and accept media interviews, and verify whether Yaben Chemical has disclosed to investors relevant information such as the possible association between Yaben Chemical's carolong anhydride products and Pfizer's new crown oral drug in the investor exchange activities, whether there is a violation of fair information disclosure and the speculation of stock prices through interactive easy to cater to market hotspots.

(4) Please combine the market capacity of the product, the changes in the market environment and the business strategy and business layout of Yaben Chemical, explain whether there have been major changes in the recent operation of Yaben Chemical and the internal and external operating environment, and explain the verification process and judgment basis, and at the same time do a good job of relevant risk warnings.

Second, the previous announcement of Yaben Chemical shows that the company's customers of caronic anhydride and its derivatives are mainly domestic customers and Indian customers, of which domestic customers account for nearly 98% of sales, and the company's sales of carolong anhydride and its derivatives in 2021 are about 27 million yuan, but Yaben Chemical said that it is unable to determine whether the company's caronic anhydride and its derivatives are indirectly supplied to Pfizer. Yaben Chemical is requested to explain the reasons why Yaben Chemical was unable to verify the end customer in combination with the specific use of caronic anhydride and its derivative products and the relevant market size, and further verify the sales to the end customer, and clearly indicate whether the carolongic anhydride and its derivatives are directly or indirectly supplied to Pfizer.

Third, on January 5, 2022, Yaben Chemical disclosed the "Reply to the Letter of Concern of the Shenzhen Stock Exchange" (hereinafter referred to as the "Reply Announcement"), according to the report "Focus on Pfizer's New Coronavirus Drug Intermediates - Isoprenol, Chrysanthemum" released by the chemical team of China International Capital Corporation Limited (hereinafter referred to as "CICC") on December 3, 2021, the carolonghydride and its derivative products produced by Yaben Chemical can be used to synthesize Pfizer's new coronavirus oral drug Palowed from the process. At the same time, Yaben Chemical quoted the content of CICC's report in the "Reply Announcement", saying that the company has a synthetic process patent for the synthesis of caromanhydride, and details can be found in the CICC report.

(1) Please explain the specific content of The REPORT quoted by Yaben Chemical in the Reply Announcement, the specific source of the relevant information obtained by Yaben Chemical from the CICC Report, whether the content of the relevant report is objective and authoritative, and whether the CICC Report can indicate that The carolong anhydride of Yaben Chemical and its derivatives can be used to synthesize Pfizer's oral drug, There is a correspondence between the patent for The carolongic anhydride product and related synthetic processes and the synthetic Pfizer drug intermediates and related synthetic process routes mentioned in CICC's report. At the same time, please explain whether Yaben Chemical has verified the accuracy of the content of CICC's report, whether Yaben Chemical has verified the technical path mentioned in CICC's report accordingly, if so, please provide supporting evidence, if not, please explain whether Yaben Chemical's mention in the announcement that carolong anhydride and its derivatives can be used to synthesize Pfizer's new crown oral drug information disclosure is suspected of being misleading statements, and please explain whether Yaben Chemical is prudent to cite CICC's report in conjunction with the above reply.

(2) According to the previous announcement of Yaben Chemical, Yaben Chemical paid 500,000 yuan for the purchase of patented technology for the production of caronic anhydride. Please provide additional information on the specific circumstances of the yaben chemical caronine synthesis process patent, including but not limited to the process of obtaining the patent, the time of acquisition and the counterparty, whether the counterparty exclusively transferred the patent to Yaben Chemical, and the specific rights of Yaben Chemical to the patent.

Please add to the further research and development process and investment of Yaben Chemical after obtaining the patent, obtain relevant approvals and certifications, patent implementation, whether there is a ownership dispute, whether it has core technical advantages, whether there is a risk of technical substitution, etc., and fully indicate the relevant risks.

(3) According to the preliminary announcement of Yaben Chemical, the company's caronic anhydride and its derivative product production line was transformed through the existing production equipment, and as of December 31, 2021, the total investment in the transformation of the above production line was RMB 6.3996 million. Please explain the reasons for the company's layout of caromanic anhydride and its derivative products and related technical and economic feasibility analysis, explain the specific time, transformation method and technical realization path of Yaben Chemical's implementation of production line transformation, and whether the relevant transformation has undergone technical acceptance.

(4) Please combine the specific contents of the relevant patents of Yaben Chemical Caroline Anhydride, the technical realization path of the company's production line transformation, and the specific technical requirements of Pfizer for the new crown oral drug Paro verde intermediates, etc., to clearly explain whether the caronic anhydride and its derivative products produced by Yaben Chemical meet the quality and technical requirements of the intermediates related to the preparation of the new crown oral drug Paloves, whether Yaben Chemical has conducted relevant technical verification, and if so, please provide supportive evidence.

(5) Please explain whether there is a situation in which Pfizer's new crown oral drug-related epidemic concept is used to speculate on stock prices in combination with the above reply, and fully warn of the relevant risks.

Fourth, Yaben Chemical's "Reply Announcement" shows that the company has a total production capacity of 20 tons / month of carolongic anhydride and its derivatives, and the recent capacity utilization rate is 70%-80%, and the company's existing production line is transformed by the existing production equipment, due to production sites, synthesis processes and other reasons, it does not have the ability to expand production. Yaben Chemical is studying and planning the capacity expansion of carolong anhydride and its derivatives, and will decide whether to expand production according to market demand and order situation. Please combine the monthly changes in the order volume in hand since the commercial mass production of Yaben Chemical Caronine, the monthly sales of carolong anhydride and its derivatives, the changes in the production and operation environment, and the response to the above questions, further explain the necessity and feasibility of Yaben Chemical's research on the expansion of production under the condition that the capacity utilization rate is not saturated, and whether it is suspected of using the media information about the possible indirect use of carolong anhydride by Pfizer new crown oral drugs to increase investor expectations and cooperate with the speculation of the company's stock price.

Fifth, please ask Yaben Chemical to verify whether there is any undisclosed information that should be disclosed, whether there are major events in the planning or other market rumors and hot concepts that may have a greater impact on the trading price of the company's stock. Please combine the macro situation of the market, the industry situation, the stock price trend of listed companies in the same industry, the production and operation of Yaben Chemical, etc., analyze in detail the reasons for the large recent increase in the stock price of Yaben Chemical, whether it matches the fundamental situation such as the company's operating performance, and further prompt the risk of the company's recent stock price increase in combination with the reply to the above questions.

Sixth, the relevant announcement disclosed by Yaben Chemical in the early stage shows that Wang Xinya, one of the actual controllers of Yaben Chemical, reduced his holding of 19 million shares of the company through block transactions on November 30, 2021, with a reduction rate of 1.97%, the average price of the reduction was 7.24 yuan, and the amount of the reduction reached 138 million yuan. Yaben Chemical is requested to verify whether the reduction is suspected of insider trading, market manipulation and other violations, and whether Yaben Chemical has used information disclosure to cooperate with the relevant shareholders to reduce their holdings.

Seventh, please explain the trading of the company's shares in the past three months by the directors, supervisors, senior management, controlling shareholders, shareholders holding more than 5% of the shares of Yaben Chemical, etc., the progress of the reduction plan disclosed in the early stage, whether there is a reduction plan and specific content in the next 3 months, and whether there is a situation of using information disclosure to cooperate with the above-mentioned personnel to reduce the holding.

Eighth, due to the irregularities in information disclosure in the pharmaceutical intermediates business of Yaben Chemical during the covid-19 epidemic period, our firm and the China Securities Regulatory Commission made disciplinary and administrative punishment decisions against Yaben Chemical and related parties in March 2020 and September 2020 respectively, and asked Yaben Chemical to carefully verify the above issues and check whether the relevant information disclosure of Yaben Chemical was true, accurate and complete, and whether there were misleading statements.

Ninth, other matters that Yamoto Chemical believes should be explained.

According to public information, Yaben Chemical was established in 2006, is a high-tech enterprise integrating R&D, production and sales in the field of life sciences, with Taicang base, Rudong base, Yancheng base and other production bases, the company landed on the Shenzhen Stock Exchange in 2011.